CN1867359B - 哌甲酯溶液及其制药用途和制备方法 - Google Patents
哌甲酯溶液及其制药用途和制备方法 Download PDFInfo
- Publication number
- CN1867359B CN1867359B CN2004800297328A CN200480029732A CN1867359B CN 1867359 B CN1867359 B CN 1867359B CN 2004800297328 A CN2004800297328 A CN 2004800297328A CN 200480029732 A CN200480029732 A CN 200480029732A CN 1867359 B CN1867359 B CN 1867359B
- Authority
- CN
- China
- Prior art keywords
- methylphenidate
- acid
- solution
- solvent
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4458—Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
T1 | 2.5 | 2.86 | 5 | 1 | 6.1 | 0.0 | 98.91 | |
T1 | 5.0 | 2.70 | 5 | 2 | 8.1 | 0.0 | 98.83 | |
T2 | 0.5 | 3.27 | 5 | 1 | 6.0 | 0.7 | 98.29 | |
T2 | 2.5 | 2.83 | 5 | 1 | 7.1 | 0.3 | 100.29 | |
T2 | 5.0 | 2.67 | 5 | 1 | 9.5 | 0.3 | 99.60 | |
T3 | 0.5 | 3.30 | 5 | 2 | 24.4 | 5.1 | 96.74 | |
T3 | 2.5 | 2.87 | 5 | 2 | 24.1 | 2.3 | 97.41 | |
T3 | 5.0 | 2.71 | 5 | 2 | 30.4 | 1.9 | 97.57 | |
T4 | 0.5 | 3.02 | 5 | 3 | 62.1 | 15.6 | 91.53 | |
T4 | 2.5 | 2.85 | 5 | 3 | 59.1 | 9.3 | 91.72 | |
T4 | 5.0 | 2.70 | 5 | 3 | 71.1 | 7.8 | 92.38 |
Claims (41)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US50970403P | 2003-10-08 | 2003-10-08 | |
US60/509,704 | 2003-10-08 | ||
PCT/US2004/033268 WO2005035000A1 (en) | 2003-10-08 | 2004-10-07 | Methylphenidate solution and associated methods of administration and production |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1867359A CN1867359A (zh) | 2006-11-22 |
CN1867359B true CN1867359B (zh) | 2010-12-15 |
Family
ID=34435016
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2004800297328A Active CN1867359B (zh) | 2003-10-08 | 2004-10-07 | 哌甲酯溶液及其制药用途和制备方法 |
Country Status (10)
Country | Link |
---|---|
US (1) | US7691880B2 (zh) |
EP (1) | EP1680144B1 (zh) |
JP (1) | JP4959335B2 (zh) |
CN (1) | CN1867359B (zh) |
AT (1) | ATE526988T1 (zh) |
AU (1) | AU2004280240B2 (zh) |
CA (1) | CA2540052C (zh) |
ES (1) | ES2373042T3 (zh) |
MX (1) | MXPA06003725A (zh) |
WO (1) | WO2005035000A1 (zh) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101797221B (zh) | 2002-12-13 | 2013-06-12 | 杜雷科特公司 | 包含高粘度液体载体材料的口服递药系统 |
CA2645855C (en) | 2006-03-16 | 2015-02-03 | Tris Pharma, Inc. | Modified release formulations containing drug-ion exchange resin complexes |
AU2008347158B8 (en) | 2007-12-06 | 2013-08-22 | Durect Corporation | Oral pharmaceutical dosage forms |
US20100260844A1 (en) | 2008-11-03 | 2010-10-14 | Scicinski Jan J | Oral pharmaceutical dosage forms |
US8287903B2 (en) | 2011-02-15 | 2012-10-16 | Tris Pharma Inc | Orally effective methylphenidate extended release powder and aqueous suspension product |
BR112015003120B1 (pt) | 2012-08-15 | 2022-08-09 | Tris Pharma , Inc | Tablete mastigável de liberação estendida de metilfenidato e seu uso |
WO2014144975A1 (en) | 2013-03-15 | 2014-09-18 | Durect Corporation | Compositions with a rheological modifier to reduce dissolution variability |
US11590228B1 (en) | 2015-09-08 | 2023-02-28 | Tris Pharma, Inc | Extended release amphetamine compositions |
CN106511264A (zh) * | 2016-11-15 | 2017-03-22 | 北京万全德众医药生物技术有限公司 | 一种盐酸哌甲酯口服溶液剂及其制备方法 |
US11590081B1 (en) | 2017-09-24 | 2023-02-28 | Tris Pharma, Inc | Extended release amphetamine tablets |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1163907A1 (en) * | 2000-06-17 | 2001-12-19 | Pharmaquest Limited | Use of l-threo-methylphenidate for the treatment of depression |
CN1352549A (zh) * | 1998-06-03 | 2002-06-05 | 阿尔扎有限公司 | 提供药物长效治疗的方法和装置 |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5354885A (en) * | 1992-12-24 | 1994-10-11 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Process for preparing ethyl ester of L-DOPA |
US6486177B2 (en) * | 1995-12-04 | 2002-11-26 | Celgene Corporation | Methods for treatment of cognitive and menopausal disorders with D-threo methylphenidate |
JP2000072674A (ja) * | 1998-08-28 | 2000-03-07 | Ota Seiyaku Kk | ノスカピン経口医薬液剤 |
US6419960B1 (en) * | 1998-12-17 | 2002-07-16 | Euro-Celtique S.A. | Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations |
JP2000247883A (ja) * | 1999-02-23 | 2000-09-12 | Fujisawa Pharmaceut Co Ltd | ジヒドロピリジン系化合物を含有する内服用液剤 |
US6127385A (en) * | 1999-03-04 | 2000-10-03 | Pharmaquest Limited | Method of treating depression using l-threo-methylphenidate |
CN1372468A (zh) * | 1999-06-02 | 2002-10-02 | 宝洁公司 | 羟乙磷酸二钠口服制剂 |
JP2001106629A (ja) * | 1999-10-04 | 2001-04-17 | Material Eng Tech Lab Inc | タンパク分解酵素阻害剤 |
IL136430A0 (en) * | 2000-05-29 | 2001-06-14 | Zviaguina Natalia | Ray tracing method and system for determining visible parts of surfaces of three-dimensional objects and their parameters of shading accounting for light and shadow volumes |
US20020103162A1 (en) * | 2000-08-28 | 2002-08-01 | Mel Epstein | Use of threo-methylphenidate compounds to enhance memory |
US20020132793A1 (en) * | 2000-08-28 | 2002-09-19 | Mel Epstein | Use of methylphenidate compounds to enhance memory |
TWI277414B (en) * | 2001-01-12 | 2007-04-01 | Baxter Int | Esmolol formulation |
MY129350A (en) * | 2001-04-25 | 2007-03-30 | Bristol Myers Squibb Co | Aripiprazole oral solution |
NZ529173A (en) * | 2001-05-25 | 2005-07-29 | Warner Lambert Co | Stable liquid pharmaceutical composition comprising a GABA analog i.e. gabapentin or pregabalin, and a polyhydric alcohol e.g. glycerol, xylitol, sorbitol, mannitol |
AR037131A1 (es) * | 2001-10-31 | 2004-10-20 | Schering Corp | Formulaciones de jarabe de ribavirina |
US6962908B2 (en) * | 2001-12-21 | 2005-11-08 | Warner Chilcott Company Inc. | Oral pharmaceutical products containing 17 β-estradiol-3-lower alkanoate, method of administering the same and process of preparation |
-
2004
- 2004-10-07 ES ES04785397T patent/ES2373042T3/es active Active
- 2004-10-07 US US10/554,133 patent/US7691880B2/en active Active
- 2004-10-07 EP EP04785397A patent/EP1680144B1/en active Active
- 2004-10-07 WO PCT/US2004/033268 patent/WO2005035000A1/en active Search and Examination
- 2004-10-07 MX MXPA06003725A patent/MXPA06003725A/es active IP Right Grant
- 2004-10-07 CA CA2540052A patent/CA2540052C/en active Active
- 2004-10-07 AT AT04785397T patent/ATE526988T1/de not_active IP Right Cessation
- 2004-10-07 AU AU2004280240A patent/AU2004280240B2/en active Active
- 2004-10-07 JP JP2006534389A patent/JP4959335B2/ja active Active
- 2004-10-07 CN CN2004800297328A patent/CN1867359B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1352549A (zh) * | 1998-06-03 | 2002-06-05 | 阿尔扎有限公司 | 提供药物长效治疗的方法和装置 |
EP1163907A1 (en) * | 2000-06-17 | 2001-12-19 | Pharmaquest Limited | Use of l-threo-methylphenidate for the treatment of depression |
Also Published As
Publication number | Publication date |
---|---|
CA2540052A1 (en) | 2005-04-21 |
EP1680144A1 (en) | 2006-07-19 |
US7691880B2 (en) | 2010-04-06 |
WO2005035000A1 (en) | 2005-04-21 |
AU2004280240B2 (en) | 2010-04-22 |
CN1867359A (zh) | 2006-11-22 |
MXPA06003725A (es) | 2006-06-23 |
EP1680144B1 (en) | 2011-10-05 |
US20060205776A1 (en) | 2006-09-14 |
CA2540052C (en) | 2012-04-10 |
JP4959335B2 (ja) | 2012-06-20 |
ES2373042T3 (es) | 2012-01-30 |
AU2004280240A1 (en) | 2005-04-21 |
ATE526988T1 (de) | 2011-10-15 |
JP2007508313A (ja) | 2007-04-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5602182A (en) | Taste masking pseudoephedrine HCL containing liquids | |
US20080014274A1 (en) | Enhanced stability phenylephrine liquid compositions | |
KR101490721B1 (ko) | 감칠맛을 가진 디페리프론용 액상 제제 | |
CN1867359B (zh) | 哌甲酯溶液及其制药用途和制备方法 | |
EP1928412B1 (en) | Aqueous anaesthetic compositions comprising propofol | |
CN106727291A (zh) | 一种盐酸托莫西汀口服溶液及其制备方法 | |
EP2316422A1 (en) | Liquid compositions comprising valsartan | |
JP3648531B2 (ja) | ファモチジン注射液 | |
JP6410814B2 (ja) | フェキソフェナジンを含む経口投与用液体医薬組成物 | |
RU2363462C2 (ru) | Фармацевтическая композиция, содержащая 5-метил-2-(2′-хлор-6′-фторанилин)фенилуксусную кислоту | |
KR101595107B1 (ko) | 플라보이드 분획 및 잔탄 검을 포함하는 경구 현탁액 형태의 약학 조성물 | |
KR101852502B1 (ko) | 조성물에 관한 개선 | |
EP2277546A1 (en) | Stable ready to use injectable paracetamol formulation | |
EP3967298A1 (en) | Aerosol composition for oral use | |
JP4607761B2 (ja) | 溶液医薬組成物 | |
US6818662B2 (en) | Pharmaceutical composition | |
JP4358535B2 (ja) | アセトアミノフェンを含有する安定な水性医薬組成物 | |
KR20140145508A (ko) | 암브록솔 및 레보드로프로피진을 포함하는 안정성이 개선된 경구용 액상 제제 | |
US20040039036A1 (en) | Water-soluble liquid internal medicine | |
US20220387363A1 (en) | Pharmaceutical liquid composition, kit of parts comprising the pharmaceutical liquid composition, and method for preparing the pharmaceutical liquid composition | |
AU6635694A (en) | Liquid antacid compositions | |
EP4279062A1 (en) | Liquid composition and its use, treatment method and kit | |
JPH08193023A (ja) | 安定な水性医薬組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C56 | Change in the name or address of the patentee | ||
CP01 | Change in the name or title of a patent holder |
Address after: American Missouri Patentee after: Mallinckrodt Inc. Address before: American Missouri Patentee before: Mallinckrodt Inc. |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20180104 Address after: The United States of Missouri, 63119 Webster groves No. 385 Marshall Street Patentee after: Thought hundred Gex Co., Ltd. Address before: American Missouri Patentee before: Mallinckrodt Inc. |